/
Founded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, AtaiBeckley is a clinical-stage biotechnology company on a mission to create breakthroughs for people with difficult-to-treat mental health conditions. Our work is grounded in rigorous science to deliver meaningful outcomes for the patients we serve.
The business is unprofitable at the operating level (-15751.06% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1227.6% YoY with margins expanding 17590.2pp.
ROIC dropped from -58.78% to -204.60%, capital efficiency is deteriorating. Negative free cash flow of -$104M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$4M
▲ +1227.6% YoY
Net Income (TTM)
-$660M
▼ -342.2% YoY
Op. Margin
-15751.06%
▲ +17590.2pp YoY
ROIC
-204.60%
▼ -145.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$104M
▼ -25.6% YoY
Op. Cash Flow (TTM)
-$103M
▼ -24.5% YoY
Net Debt
$52M
Cash & Equiv.
$85M
Continue Research